PE20081636A1 - Inhibidores de antranilamida para aurora quinasa - Google Patents
Inhibidores de antranilamida para aurora quinasaInfo
- Publication number
- PE20081636A1 PE20081636A1 PE2008000182A PE2008000182A PE20081636A1 PE 20081636 A1 PE20081636 A1 PE 20081636A1 PE 2008000182 A PE2008000182 A PE 2008000182A PE 2008000182 A PE2008000182 A PE 2008000182A PE 20081636 A1 PE20081636 A1 PE 20081636A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- amino
- inhibitors
- aurora kinase
- pyrimidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ANTRANILAMIDA DE FORMULA (I) DONDE R1 ES H, COOH, ALCOXI(C1-C6), CF3, ENTRE OTROS; R2 ES H, HALO, ALQUILO(C1-C3), CN, ENTRE OTROS; R3 ES H, FENILO, MORFOLINO-CH2CH2-FENILO, ENTRE OTROS; R4 ES HALO, ALQUILO(C1-C3) O ALCOXI(C1-C3); r ES DE 1 A 3; s ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: 2-{[5-FLUORO-2-({3-[2-(4-MORFOLINIL)ETIL]FENIL}AMINO)-4-PIRIMIDINIL]AMINO}-N-(2-HIDROXIETIL)BENZAMIDA, (3R)-1-({2-[(5-FLUORO-2-{[3-(4-METIL-1-PIPERAZINIL)FENIL]AMINO}-4-PIRIMIDINIL)AMINO]FENIL}CARBONIL)-3-PIRROLIDINOL, (3R)-1-[(2-{[5-METIL-2-({3-[2-(4-MORFOLINIL)ETIL]FENIL}AMINO)-4-PIRIMIDINIL]AMINO}FENIL)CARBONIL]-3-PIRROLIDINOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA AURORA QUINASA SIENDO UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88667607P | 2007-01-26 | 2007-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081636A1 true PE20081636A1 (es) | 2009-01-10 |
Family
ID=39644890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000182A PE20081636A1 (es) | 2007-01-26 | 2008-01-24 | Inhibidores de antranilamida para aurora quinasa |
Country Status (10)
Country | Link |
---|---|
US (2) | US7625903B2 (es) |
EP (1) | EP2121637A4 (es) |
JP (1) | JP5337712B2 (es) |
AR (1) | AR065015A1 (es) |
AU (1) | AU2008207809B2 (es) |
CA (1) | CA2676257A1 (es) |
CL (1) | CL2008000197A1 (es) |
PE (1) | PE20081636A1 (es) |
TW (1) | TW200902010A (es) |
WO (1) | WO2008092049A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1849318B (zh) | 2003-07-30 | 2011-10-12 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法 |
AR065015A1 (es) * | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
ES2645689T3 (es) | 2008-05-21 | 2017-12-07 | Ariad Pharmaceuticals, Inc. | Derivados de fósforo como inhibidores de quinasas |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
RU2536584C2 (ru) | 2008-06-27 | 2014-12-27 | Авила Терапьютикс, Инк. | Гетероарильные соединения и их применение |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
CN101585781B (zh) * | 2009-07-08 | 2012-08-08 | 北京颖新泰康国际贸易有限公司 | 一种邻氨基-n,n-二甲基苯甲酰胺的制备方法 |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
CN101973956B (zh) * | 2010-09-26 | 2013-07-31 | 合肥星宇化学有限责任公司 | 靛红酸酐的合成方法及n-异丙基-2-氨基苯甲酰胺的合成方法 |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
CN103269704B (zh) | 2010-11-01 | 2018-07-06 | 西建卡尔有限责任公司 | 杂环化合物和其用途 |
ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
CN102173999A (zh) * | 2011-02-28 | 2011-09-07 | 盐城工学院 | 一种2-氨基-n,n-二甲基苯甲酰胺的合成方法 |
WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
PL2693881T3 (pl) * | 2011-04-01 | 2020-03-31 | University Of Utah Research Foundation | Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL |
KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
EP2770830A4 (en) | 2011-10-28 | 2015-05-27 | Celgene Avilomics Res Inc | METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE) |
WO2013075167A1 (en) * | 2011-11-21 | 2013-05-30 | Cancer Therapeutics Crc Pty Ltd | Binding agent |
RS57901B1 (sr) | 2012-03-15 | 2019-01-31 | Celgene Car Llc | Soli inhibitora kinaze receptora epidermalnog faktora rasta |
MX356753B (es) | 2012-03-15 | 2018-06-12 | Celgene Avilomics Res Inc | Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
GB201214106D0 (en) * | 2012-08-07 | 2012-09-19 | Univ Strathclyde | Immunomodulatory compounds |
KR102455889B1 (ko) | 2012-11-21 | 2022-10-17 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 bmi-1 저해제 |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EA201591051A1 (ru) | 2013-02-08 | 2016-06-30 | Селджен Авиломикс Рисерч, Инк. | Ингибиторы erk и варианты их применения |
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
JP6524094B2 (ja) | 2013-08-30 | 2019-06-05 | ピーティーシー セラピューティクス, インコーポレイテッド | 置換ピリミジンBmi−1阻害剤 |
WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
CN105017160B (zh) * | 2015-06-24 | 2017-12-29 | 温州医科大学 | 一种嘧啶类egfrt790m抑制剂及其合成方法和应用 |
CN106187914B (zh) * | 2016-07-12 | 2019-03-15 | 黄河三角洲京博化工研究院有限公司 | 一种2,4-二氯-5-甲氧基嘧啶的制备方法 |
SG10201913464TA (en) * | 2016-12-19 | 2020-03-30 | Epizyme Inc | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
WO2019232225A1 (en) * | 2018-05-30 | 2019-12-05 | Promega Corporation | Broad-spectrum kinase binding agents |
CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
SG11202101085PA (en) | 2018-08-27 | 2021-03-30 | Sumitomo Dainippon Pharma Co Ltd | Optically active azabicyclic derivative |
EP4153770A2 (en) * | 2020-05-22 | 2023-03-29 | Promega Corporation | Enhancement of kinase target engagement |
CN113061117B (zh) * | 2021-03-30 | 2023-02-10 | 长治学院 | 一种2-((5-氯-2-(4-吗啉甲基苯胺基)嘧啶-4-基)氨基)苯甲酰胺衍生物 |
WO2023134582A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海立森印迹医药技术有限公司 | 一种嘧啶-2,4-二胺衍生物及其制备方法和用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60017898T2 (de) | 1999-06-09 | 2006-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | Neuartige heterocyclische carboxamidderivate |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
BR0209485A (pt) * | 2001-05-08 | 2004-07-06 | Schering Ag | Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3 |
MXPA04004176A (es) | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa. |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
BR0308921B1 (pt) * | 2002-03-28 | 2013-11-19 | Composição de resinato de monômero de ácido graxo, seu processo de preparação, tinta de impressão e verniz de tinta de impressão | |
WO2004074244A2 (en) * | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
SG145749A1 (en) | 2003-08-15 | 2008-09-29 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
US20070105839A1 (en) * | 2003-09-18 | 2007-05-10 | Patricia Imbach | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
CA2640398A1 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
CN101563327A (zh) | 2006-12-19 | 2009-10-21 | 健泰科生物技术公司 | 嘧啶类激酶抑制剂 |
AR065015A1 (es) * | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
AU2008229147A1 (en) | 2007-03-20 | 2008-09-25 | Smithkline Beecham Corporation | Chemical compounds |
-
2008
- 2008-01-24 AR ARP080100292A patent/AR065015A1/es unknown
- 2008-01-24 PE PE2008000182A patent/PE20081636A1/es not_active Application Discontinuation
- 2008-01-24 CL CL200800197A patent/CL2008000197A1/es unknown
- 2008-01-24 TW TW097102587A patent/TW200902010A/zh unknown
- 2008-01-25 US US12/019,730 patent/US7625903B2/en not_active Expired - Fee Related
- 2008-01-25 CA CA002676257A patent/CA2676257A1/en not_active Abandoned
- 2008-01-25 WO PCT/US2008/051985 patent/WO2008092049A1/en active Application Filing
- 2008-01-25 AU AU2008207809A patent/AU2008207809B2/en not_active Ceased
- 2008-01-25 JP JP2009547435A patent/JP5337712B2/ja not_active Expired - Fee Related
- 2008-01-25 EP EP08728247A patent/EP2121637A4/en not_active Withdrawn
- 2008-01-25 US US12/524,009 patent/US7884098B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2008207809A1 (en) | 2008-07-31 |
JP5337712B2 (ja) | 2013-11-06 |
US7625903B2 (en) | 2009-12-01 |
WO2008092049A1 (en) | 2008-07-31 |
TW200902010A (en) | 2009-01-16 |
AU2008207809B2 (en) | 2013-04-18 |
US20100016318A1 (en) | 2010-01-21 |
JP2010516780A (ja) | 2010-05-20 |
US7884098B2 (en) | 2011-02-08 |
CL2008000197A1 (es) | 2008-08-01 |
AR065015A1 (es) | 2009-05-13 |
CA2676257A1 (en) | 2008-07-31 |
EP2121637A1 (en) | 2009-11-25 |
US20080182852A1 (en) | 2008-07-31 |
EP2121637A4 (en) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081636A1 (es) | Inhibidores de antranilamida para aurora quinasa | |
PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
PE20140502A1 (es) | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
PE20091816A1 (es) | Inhibidores de bace | |
AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
PE20080362A1 (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
EA200601896A1 (ru) | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv | |
PE20110598A1 (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
AR059249A1 (es) | Compuesto amina trisustituido | |
PE20110341A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20090972A1 (es) | Inhibidores de quinasa c-fms | |
PE20100083A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
PE20090243A1 (es) | Compuestos de imidazol sustituido como inhibidores de renina | |
RS52590B (en) | SUBSTITUTIONED QUINOXALINE TYPE COMPONENTS WITH THE USED PIPERIDINE AND THEIR USE | |
PE20061394A1 (es) | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas | |
PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
PE20091243A1 (es) | Compuesto heterociclico fusionado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |